AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Axillary Hyperhidrosis Market Insight, Epidemiology and Market Forecast Report 2020-2030 - ResearchAndMarkets.com

December 4, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Dec 4, 2020--

The “Axillary Hyperhidrosis - Market Insight, Epidemiology and Market Forecast - 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This ‘Axillary Hyperhidrosis (AH) -Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the Axillary Hyperhidrosis (AH), historical and forecasted epidemiology as well as the Axillary Hyperhidrosis (AH) market trends in the United States.

ADVERTISEMENT

The Axillary Hyperhidrosis (AH) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted US Axillary Hyperhidrosis (AH) market size from 2017 to 2030. The Report also covers current Axillary Hyperhidrosis (AH) treatment practice/algorithm, market drivers, market barriers, unmet medical needs, SWOT analysis to curate the best of the opportunities, and assesses the underlying potential of the market.

Axillary Hyperhidrosis (AH) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Axillary Hyperhidrosis, Diagnosed Prevalence of Axillary Hyperhidrosis, Age-specific Diagnosed Prevalent Cases of Axillary Hyperhidrosis, Type-specific Diagnosed Prevalent Cases of Axillary Hyperhidrosis, and Severity-specific Diagnosed Prevalent Cases of Axillary Hyperhidrosis in the United States from 2017 to 2030.

Key Findings

  • As per the analysis, there was a total of 10,162,438 Axillary Hyperhidrosis prevalent cases in 2017.
  • As per the analysis, a total of 3,048,732 Axillary Hyperhidrosis cases were diagnosed in 2017.
  • In 2017, 327,129 cases accounted for < 18 years, 1,635,035 cases for 18-39 years, 872,852 cases for 40-64 years and 213,716 cases for 65+ years.
  • As per the analysis, a total of 3,048,732 Axillary Hyperhidrosis cases were diagnosed in 2017, Out of which 93% accounted for Primary hyperhidrosis and 7% accounted for secondary hyperhidrosis.
  • Out of the total diagnosed cases in the US, in 2017, 52% accounted for severe HDSS scale 3 or 4 and 48% accounted for Non-severe HDSS scale 1 or 2.

ADVERTISEMENT

Axillary Hyperhidrosis (AH) Market Outlook

The treatment of axillary hyperhidrosis involves antiperspirants Qbrexza, Botox, miraDry, oral medications, surgery, and other procedures.

The first line-of-defense against excessive underarm sweating are antiperspirants. Antiperspirants are non-invasive, topical, and are available in several different strengths, including “regular” over-the-counter products, “clinical strength” over-the-counter products, and perhaps even prescription antiperspirants. The recent advent of clinical strength antiperspirants have shown the same level of sweat management as prescription products, but with much less irritation. Drysol (aluminum chloride [hexahydrate] 20% topical solution) is approved by the US FDA as an astringent to be used to aid in the management of axillary hyperhidrosis.

In 2018, the US FDA approved Qbrexza (glycopyrronium tosylate), an anticholinergic, for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. It is a once-daily anticholinergic cloth containing 105 mg glycopyrronium tosylate, equivalent to 66 mg of glycopyrronium. The International Hyperhidrosis Society recommends Qbrexza and topical antiperspirants as the first-line treatment for PAH.

Botox (onabotulinumtoxinA) is an injectable, purified protein, acetylcholine release inhibitor, and a neuromuscular blocking agent. It is administered intradermally and approved by the US FDA for the treatment of PAH in patients, who were unable to obtain relief using topical agents. Several other versions of botox such as Myobloc, Dysport, Xeomin, etc. are available in the US. However, they are not approved for the treatment of axillary hyperhidrosis. It is usually preferred for patients failed to topical therapies or have severe disease. In January 2011, the miraDry system was cleared by the FDA through the 510(k) process for treating PAH. This is a microwave device designed to heat tissue at the dermal-hypodermal interface, the location of the sweat glands. Treatment consists of two sessions of approximately 1 h in duration.

Oral medications such as anticholinergics, beta-blockers, and benzodiazepines work systemically to reduce sweating. They are usually referred to patients who do not benefit from other therapies like clinical strength antiperspirants, iontophoresis, Botox, or a customized combination of these. Anticholingergics include glycopyrrolate, oxybutynin, benztropine, propantheline, etc. Long-term use of anticholinergics is found to have a potential link between the developments of dementia and/or brain atrophy.

Most of the patients get benefited from antiperspirants, Botox injections, miraDry, or a combination of these hyperhidrosis treatments (or these treatments combined with an oral medication). In most severe cases, patients may seek a surgical approach to treat their axillary hyperhidrosis, such as excision, curettage, liposuction, and laser. Combinations of curettage and central excision, or of curettage and liposuction may be used, as well as combinations of liposuction and laser treatments. Dermatologists often have good results with these techniques. There are few approved therapies and procedures by the US FDA for this indication such as Drysol, botulinum toxin (Botox), miraDry, and Qbrexza. According to the publisher, ICCA US is expected to change in the study period 2017-2030.

Key Findings

  • The market size for Axillary Hyperhidrosis was USD 482.53 million in 2017 in the US.
  • In 2017, the total market of Axillary Hyperhidrosis was USD 482.53 million which includes USD 351.21 million for topical Therapies; USD 64.11 million for Oral Systemic therapies, and USD 67.20 million for Intradermal Botulinum toxin injections.
  • Apart from these therapies, few emerging therapies are also expected to launch in the forecast period (2020-2030). Both emerging therapies (1% Glycopyrronium Bromide (GPB); Sofpironium bromide (BBI-4000)) have a similar molecule type (small molecule) and topical route of administration. These therapies are expected to launch in the year 2023.

     

Key Topics Covered:

1 Key Insights

2 Executive Summary of Axillary Hyperhidrosis (AH)

3 Disease Background and Overview: Axillary Hyperhidrosis

3.1. Introduction

3.2. Types and Underlying Causes of Hyperhidrosis

3.3. Symptoms of Axillary hyperhidrosis

3.4. Pathophysiology of Axillary hyperhidrosis

3.5. Diagnosis

3.5.1. Diagnostic Algorithm

4 Patient Journey

5 Epidemiology and Patient Population

5.1 Key Findings

5.2 KOL Views

5.3 Epidemiology Methodology

5.4 Assumptions and Rationale

5.5 Total Prevalent Cases of Axillary Hyperhidrosis in the United States

5.6 Diagnosed Prevalent Cases of Axillary Hyperhidrosis in the United States

5.7 Age-specific Diagnosed Prevalent Cases of Axillary Hyperhidrosis in the United States

5.8 Type-Specific Diagnosed Prevalent Cases of Axillary Hyperhidrosis in the United States

5.9 Severity Specific Diagnosed Prevalent Cases of Axillary Hyperhidrosis in the United States

6 Current Treatment and Medical Practices

6.1. Treatment Algorithm

6.2. Treatment Guideline

7 Unmet Needs

8 Marketed Drugs

8.1. Botox (OnabotulinumtoxinA): Allergan

8.1.1. Product Description

8.1.2. Regulatory Milestones

8.1.3. Other Development Activities

8.1.4. Clinical Development

8.1.5. Safety and Efficacy

8.1.6. Product Profile

8.2. Qbrexza (Glycopyrronium tosylate): Dermira

9 Emerging Drugs

9.1. WO3970 (1% Glycopyrronium Bromide): Dr. August Wolff GmbH & Co. KG Arzneimittel

9.1.1. Product Description

9.1.2. Other Development Activities

9.1.3. Clinical Development

9.1.4. Safety and Efficacy

9.1.5. Product Profile

9.2. Sofpironium Bromide (BBI-4000): Brickell Biotech/Kaken Pharmaceutical

9.3. DMVT-504 (THVD-102, Oxybutynin/pilocarpine): Dermavant Sciences/TheraVida

10 Axillary Hyperhidrosis (AH): Market Analysis

10.1 Key Findings

10.2 Market Methodology

10.3 Attribute Analysis

10.4 Key Market Forecast Assumptions

11 United States Market Outlook

11.1 United States Market Size

11.1.1. Total market size of Axillary Hyperhidrosis in the United States

11.1.2. Market Size of Axillary Hyperhidrosis by Therapies in the US

12 Market Drivers

13 Market Barriers

14 SWOT Analysis

15 Reimbursement and Market Access

16 Appendix

Companies Mentioned

  • Allergan
  • Dermira
  • Dr. August Wolff GmbH & Co. KG Arzneimittel
  • Brickell Biotech/Kaken Pharmaceutical
  • Dermavant Sciences/TheraVida

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/kyyeb9

View source version on businesswire.com:https://www.businesswire.com/news/home/20201204005322/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 12/04/2020 08:18 AM/DISC: 12/04/2020 08:18 AM

http://www.businesswire.com/news/home/20201204005322/en